2) SLAMF7, was further assessed due to its implications for possible combination therapy with elotuzumab, a monoclonal antibody targeting SLAMF7 which is already used in MM patient care (Gentile et al., 2021). This evidence concerns the gene SLAMF7 and Miyoshi myopathy.